As of September 30, 2023, VYNE had cash and cash equivalents and restricted cash of $15.5 million. When adding the gross proceeds received from the PIPE, VYNE’s cash and cash equivalents and restricted cash as of September 30, 2023 would have been approximately $103.7 million. VYNE currently anticipates that its cash and cash equivalents and restricted cash as of September 30, 2023, together with the gross proceeds from the PIPE, will be sufficient to fund its operations through the end of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VYNE:
- VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- VYNE Therapeutics to host virtual research and development day
- VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
- VYNE Therapeutics price target lowered to $5.75 from $28 at H.C. Wainwright
- VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202
